Technology · Issue 01
The first drug class to bend obesity
Obesity medicines did $66 billion of list-price business in 2025. IQVIA sees $92 billion this year. WHO still expects the condition to double by 2030 — and the shots to reach fewer than one in ten who need them.
- Obesity-medicine sales, 2025
- $66bn
- IQVIA 2026 path
- $92bn
- Of people who could benefit, even in 2030
- <10%
- Deaths associated with obesity, 2024
- 3.7m
A metabolic general-purpose technology
IQVIA’s April 2026 outlook is the print to use: $66 billion of list-price obesity-medicine sales in 2025, $92 billion pencilled for 2026, and a fan of $105–200 billion after that. Reuters, covering Lilly’s August 2026 quarter, repeats the $66 billion. Oral Wegovy reached US pharmacies in January; Lilly’s pill followed in April. This is no longer a Danish specialty. It is a manufacturing, payer and behaviour shock — closer to the statin than to the latest oncology story — and it is still, on WHO’s December 2025 guideline, going to reach fewer than 10% of the people who could benefit by 2030.
The body is a slower chart than the ticker
WHO: obesity was associated with 3.7 million deaths in 2024, more than a billion people live with it, and the count is projected to double by 2030, at an economic cost approaching $3 trillion a year. Gallup’s US adult obesity reading has eased from 39.9% in 2022 to 36.4% in 2026 as GLP-1 use among adults went from 3% to 11% — a national experiment, not yet a global one. Semaglutide lost exclusivity in India, China, Brazil, Turkey and Canada in early 2026, markets that hold 38% of adults with obesity. The rich-world branded duopoly and the rest-of-world generic wave are the same molecule living two lives.
What the long view actually buys
Pair this with The age of fewer children and The factory of robots. A world that is older, more automated and suddenly less hungry is a different consumer-staples book, a different airline-seat book, a different joint-replacement book. The investing mistake is to treat 2026 sales growth as a permanent 40% CAGR, or to ignore the second-order losers (snacks, soda, some med-tech volumes) that have not yet shown up in the numbers. The investing discipline is to own manufacturing capacity, oral follow-ons and payers who can still say no — and to remember WHO’s <10% access line. Most of the world is not on the shot.
Investing lens
Horizon 5–12 years · Educational, not advice
GLP-1s are a manufacturing and payer story now, a consumer-staples and healthcare-volume story next. Own the scarce fill-finish and the oral follow-on; size the branded duopoly as if a generic and a pill already exist, because they do.
Where the map points
- Incumbent incretin franchises, sized for patent and pill risk
- Fill-finish, devices, and CDMO capacity
- Selective short or underweight on the most exposed snack and soda names
- Do not build a 2030 model that assumes 40% of adults on therapy
What can break it
- Payer backlash and cash-pay exhaustion
- Oral and generic erosion from 2026
- Muscle-loss and discontinuation data that cap duration
CHART does not recommend securities, funds or trades. Figures can be revised by their publishers. Do your own research and consider regulated advice before allocating capital.
Sources
Every headline number traces to a named publisher. Contextual sources inform the essay, not the key stat.
- 01PrimaryIQVIA2026-04-21The outlook for obesity from 2026 to 2030
Global obesity-medicines market $66 billion list-price in 2025; $92 billion forecast for 2026; $105–200 billion thereafter. Oral Wegovy launched US January 2026.
- 02PrimaryWorld Health Organization2025-12-01WHO issues global guideline on the use of GLP-1 medicines in treating obesity
Obesity associated with 3.7 million deaths in 2024; projected to double by 2030. GLP-1s reach <10% of those who could benefit by 2030 even with rapid scale-up. Economic cost ~$3 trillion a year by 2030.
- 03CorroboratedReuters2026-08-05Lilly beats estimates on injectable GLP-1 demand
Confirms IQVIA $66 billion 2025 obesity-drug market. Lilly Mounjaro $9.94 billion and Zepbound $4.93 billion in the quarter.
Keep reading
The age of fewer children
Global fertility is 2.25 and falling through replacement in the 2030s. The 21st century’s quietest mega-trend is a smaller next generation.
2.25
Global total fertility rate (UN WPP 2024)
Seven names, a third of the S&P
Apple, Microsoft, Nvidia, Amazon, Alphabet, Meta and Tesla were 34% of the S&P 500 in August 2026 — about $24 trillion in one corridor of the market.
33.9%
Magnificent 7 share of the S&P 500, Aug 2026
China installed half the world’s robots
In 2024 the world’s factories took 542,000 new industrial robots. 295,000 of them went to China — more than the rest of Earth combined.
54%
China’s share of new industrial robots, 2024